Skip to content

Pneumodilation Or Endoscopic Myotomy in Achalasia trial

Pneumodilation Or Endoscopic Myotomy in Achalasia trial - POEMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39025
Enrollment
65
Registered
2012-07-11
Start date
2012-09-21
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia Oesophageal motility disorder

Interventions

Study subjects undergo a POEM or endoscopic pneumodilatation Per-oral endoscopic submucosal myotomy (POEM): The POEM tehcnique is entirely endoscopic. Using an endoscopic knife, an entry to the subm

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Presence of achalasia, as shown on oesophageal manometry - Eckardt score > 3 - Age between 18-80 years - Signed written informed consent - ASA class I or II

Exclusion criteria

Exclusion criteria: - Previous endoscopic or surgical treatment for achalasia, except botulinium toxin injections - Previous surgery of the stomach or oesophagus - Patients with known coagulopathy - Presence of liver cirrhosis and/or oesophageal varices - Presence of eosinophilic oesophagitis - Presence of Barrett*s oesophagus - Pregnancy at time of treatment - Presence of a stricture of the oesophagus - Presence of malignant or premalignant oesophageal lesions - Presence of an extensive, tortuous dilated oesophageal body (S-shape) - Presence of a diverticula in the distal oesophagus

Design outcomes

Primary

MeasureTime frame
Primary endpoint is treatment success, defined as an Eckardt score of 3 or less in the absence of the need for endoscopic or surgical retreatment and the absence of severe complications associated with treatment. The primary endpoint is measured after two years, but follow up is continued up to 5 years.

Secondary

MeasureTime frame
- Quality of life and achalasia-specific quality of life - Stasis in the oesophagus, measured with a timed barium oesophagogram - Presence of reflux symptoms, reflux oesophagitis and excessive oesophageal acid exposure - Lower oesophageal sphincter pressure and integrative relaxation pressure (IRP4), as measured with high-resolution manometry - Complications of the treatment, defined as any unwanted events that arise following treatment and/or that are secondary to the treatment. Complications are classified as *severe* when these result in admission > 24 hours or prolongation of an already planned admission of >24 hours, admission to a medium or intensive care unit, additional endoscopic procedures, or blood transfusion or death. Other complications are classified as *mild*. - The need for endoscopic or surgical retreatment after the initial treatment session

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)